Back
Arcutis Biotherapeutics Inc (ARQT)
BiotechnologyARQT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$26.56
+8.45%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-0.13
ROE
-1.4%
Gross margin
90.9%
Debt/Equity
0.60x
Revenue growth
60.1%
Arcutis Biotherapeutics Inc — company intelligence
Earnings surprises
Q2 2026$0.11 vs $0.04 est+150.6%
Q1 2026$-0.09 vs $-0.08 est-7.4%
Q4 2025$0.13 vs $0.12 est+12.4%
Q3 2025$0.06 vs $-0.10 est+158.9%
Analyst consensus · 14 analysts
12 Buy2 Hold0 Sell
Updated Oct 8, 2026
Insider activity · 90 days
3 buys4 sellsnet +27,521 shares
Curran Terrieother 11,148 · Aug 27, 2026
Curran Terrieother 27,052 · Aug 27, 2026
Curran Terrieother 1,072 · Aug 20, 2026
Recent SEC filings
4 — Insider transaction reportSep 18, 2026
4 — Insider transaction reportSep 17, 2026
4 — Insider transaction reportSep 10, 2026
Latest news
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award — Yahoo · 4d ago
Arcutis Biotherapeutics: An Emerging GARP Stock — SeekingAlpha · 4d ago
Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade) — SeekingAlpha · 4d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.